Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers |
| |
| Authors: | David M. Gill Neeraj Agarwal |
| |
| Affiliation: | Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT |
| |
| Abstract: | The recent resurgence of immunotherapy has transformed the therapeutic field of advanced urologic cancers. In this seminars issue, we evaluate the role of emerging and recently approved immunotherapeutic agents in advanced prostate, urothelial, and renal cell carcinoma. In each of these fields, we discuss recent regulatory approvals as well as promising ongoing clinical trials. Finally, we discuss incidence and management of immune related adverse events specifically associated with PD-1/PD-L1 inhibitors. |
| |
| Keywords: | Systemic immunotherapy Urologic oncology Checkpoint inhibitors Cancer vaccines |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
